0.70
+0.0571(+8.92%)
Currency In USD
| Previous Close | 0.64 |
| Open | 0.65 |
| Day High | 0.72 |
| Day Low | 0.65 |
| 52-Week High | 5.62 |
| 52-Week Low | 0.58 |
| Volume | 552,281 |
| Average Volume | 348,195 |
| Market Cap | 26.67M |
| PE | -3.32 |
| EPS | -0.21 |
| Moving Average 50 Days | 0.8 |
| Moving Average 200 Days | 1.67 |
| Change | 0.06 |
If you invested $1000 in FibroBiologics, Inc. Common Stock (FBLG) since IPO date, it would be worth $39.83 as of July 16, 2025 at a share price of $0.697. Whereas If you bought $1000 worth of FibroBiologics, Inc. Common Stock (FBLG) shares 6 months ago, it would be worth $364.97 as of July 16, 2025 at a share price of $0.697.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
FibroBiologics to Present at the Advanced Wound Care Summit USA
GlobeNewswire Inc.
Jul 11, 2025 12:30 PM GMT
HOUSTON, July 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for c
FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank
GlobeNewswire Inc.
Jul 09, 2025 12:30 PM GMT
HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for c
FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10
GlobeNewswire Inc.
Jul 07, 2025 8:35 PM GMT
HOUSTON, July 07, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for c